Bioreactors News and Research

RSS

Alnylam Biotherapeutics presents new data on RNAi technologies at Cell Culture Engineering XII

Alnylam Biotherapeutics, a division of Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the presentation of new data at the Cell Culture Engineering XII conference held in Alberta, Canada from April 25 - 30, 2010. Alnylam Biotherapeutics was formed by Alnylam to develop RNAi technologies for application in manufacturing processes for biotherapeutic products, including recombinant proteins and monoclonal antibodies.

4 May 2010

Sartorius Group's first-quarter consolidated sales revenue increases by 3.0% to 150.4 million euros

At today's Annual Shareholders' Meeting of the Sartorius technology group, CEO and Executive Board Chairman Dr. Joachim Kreuzburg presented the consolidated results for the first three months of 2010. The Biotechnology Division, which operates under the name Sartorius Stedim Biotech and contributes a good two-thirds to consolidated sales, started off the year 2010 by reporting growth and further profitability gains again.

From Sartorius 22 Apr 2010

Avid Bioservices highlights data of single-use bioreactors and traditional stainless steel bioreactors

Avid Bioservices, Inc. today presented data highlighting the comparability of production run performance between the company's single-use bioreactors (Thermo Scientific HyClone S.U.B.) and its traditional stainless steel bioreactors at the Thermo Scientific BioProduction Optimization Workshop in San Francisco, California.

From Thermo Fisher Scientific Inc. 17 Mar 2010

Growing human therapeutic proteins in algae can help reduce cancer treatment cost

Pharmaceutical companies could substantially reduce the expense of costly treatments for cancer and other diseases produced from mammalian or bacterial cells by growing these human therapeutic proteins in algae-rapidly growing aquatic plant cells that have recently gained attention for their ability to produce biofuels.

9 Mar 2010

Humacyte, Xcellerex collaborate to develop novel vascular graft for transplantation technologies

Humacyte, Inc. and Xcellerex, Inc. have entered into an initial strategic collaboration for Xcellerex to develop a novel manufacturing process that will enable the production of Humacyte’s lead regenerative medicine product using Xcellerex’s XDR single use bioreactor system in its FlexFactory®. Humacyte’s product is a large diameter vascular graft that is based on its innovative and proprietary platform technology for engineering human, extracellular matrix-based tissues that have properties that are similar to native tissues.

5 Mar 2010

Shire receives FDA Fast Track designation for REPLAGAL

Shire plc, the global specialty biopharmaceutical company, announces it has received Fast Track designation from the FDA for REPLAGAL(R) (agalsidase alfa), its enzyme replacement therapy for Fabry disease.

24 Feb 2010

Cantimer, Advanced Instruments announce license and product development agreement

Cantimer, Inc., and Advanced Instruments, Inc. today jointly announced that the two companies had signed a license and product development agreement. Under the terms of the license agreement, Advanced Instruments received an exclusive license to Cantimer's unique sensor technology for select applications in the biotech market.

23 Feb 2010

TAP to showcase ambr system at Cell Line Development and Engineering 2010

The Automation Partnership, a world leader in the design and development of innovative automation for life science applications, is pleased to announce it will be showcasing its new advanced micro bioreactor system (ambr™) at Cell Line Development and Engineering 2010, February 25-26 in San Francisco, USA.

15 Feb 2010

TAP and EPSRC Centre for Innovative Manufacturing in Regenerative Medicine continue collaboration

The Automation Partnership (TAP), a world leader in the design and development of innovative automation for life science applications is pleased to announce that its collaboration with leading translational research group, the EPSRC Centre for Innovative Manufacturing in Regenerative Medicine at Loughborough University is to continue into a second five year phase. This follows the recent announcement by Prime Minister, Gordon Brown and Lord Mandelson, UK Secretary of State, Department for Business, Innovation and Skills of a £5.33 million grant to the centre.

19 Jan 2010

Pall acquires U.S. biotechnology company

Pall Corporation, a global leader in filtration, separation and purification, today announced its acquisition of MicroReactor Technologies, Inc. (MRT), a privately held U.S. biotechnology company. MRT has developed a reliable, easy-to-use and cost-effective miniature bioreactor technology platform.

From Pall Corporation 12 Jan 2010

Alternative, fast and safe process for producing large quantities of effective flu vaccines

A shortage of flu vaccines may soon become a problem of the past. Researcher Manon Cox has developed an alternative process for producing large quantities of safe and effective vaccines at twice to four times the usual speed. The process is based on using cells in bioreactors instead of fertilised chicken's eggs, which have a limited availability.

9 Dec 2009

The Automation Partnership's ambr technology to be previewed at the Bioprocess International Conference

The Automation Partnership (TAP), a world leader in the design and development of innovative automation for life science applications, is exclusively previewing its Advanced Microscale BioReactor (ambr™) technology on Booth 914 at the Bioprocess International Conference in Raleigh, USA.

13 Oct 2009

SAFC Pharma expands contract manufacturing services

SAFC Pharma®, a business segment of SAFC®, a member of the Sigma-Aldrich® Group, today announced the completion of an addition to its Carlsbad, Calif., facility that expands the Company's contract manufacturing services for its late phase and commercial clients.

13 Oct 2009

NIH grants $5 million to Pittsburgh researchers

Regenerative medicine researchers at the University of Pittsburgh received two grants totaling more than $5 million from the National Institutes of Health (NIH) to explore new methods for cultivating replacement cells from existing tissues and organs.

26 Sep 2009

Update on Cerezyme and Fabrazyme supply from Genzyme Corporation

Genzyme Corporation (NASDAQ: GENZ) today provided an update on its progress to restore supplies of Cerezyme® (imiglucerase for injection) and Fabrazyme® (agalsidase beta) for patients worldwide and revised its 2009 revenue guidance for these products.

24 Sep 2009

Genzyme updates on Cerezyme supply plus 2009 financials

Genzyme Corporation (NASDAQ: GENZ) today provided an update on the impact of Cerezyme® (imiglucerase for injection) supply constraints on patient treatment regimens and on the company’s 2009 financial results. The company’s Fabrazyme® (agalsidase beta) supply constraint period, Fabrazyme dose conservation guidelines for patients, and Fabrazyme financial guidance are unchanged.

11 Aug 2009

Bioprocess increases vaccine yield

Empa researchers have managed to adapt a process for manufacturing certain vaccines - in particular that against Haemophilus influenzæ bacteria - for use in bioreactors, with the result that the yield is enhanced enormously.

12 Jun 2009

SAFC Pharma augments assay development capabilities

SAFC Pharma, a business segment of SAFC, a member of the Sigma-Aldrich group, today announced that it has commenced operations at its 7,000 sq. ft. state-of-the-art laboratory complex in Carlsbad, CA.

29 Jan 2009

Bone repair using patient's stem cells comes closer

Hitherto it has been difficult to induce adult human stem cells to produce bone, e.g. in order to repair bone tissue. Researchers at the University of Twente have shown that if the enzyme PKA is previously activated in the stem cells in the lab, following implantation this results in substantial bone formation.

26 May 2008

Researchers increase in vivo lifetime of nanoparticles

Researchers at the University of California, Santa Barbara have discovered that attaching polymeric nanoparticles to the surface of red blood cells dramatically increases the in vivo lifetime of the nanoparticles.

29 Jun 2007